Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens. Neoantigens are protein markers unique to each individual that are expressed on the surface of every cancer cell and can be detected by the immune system. Achilles uses DNA sequencing data from each patient together with its proprietary AI-powered bioinformatics platform, PELEUS™, to identify patient-specific clonal neoantigens that enable the development of personalized cell therapies using our VELOS™ manufacturing process.
VELOS™ creates a clonal neoantigen-reactive T cell product, or cNeT, by using the power of natural antigen presentation by dendritic cells to selectively expand T cells that are reactive against the identified clonal neoantigens. cNeT products target multiple clonal neoantigens in a patient and exploit cancer’s Achilles heel, allowing precision treatments that destroy tumors without harming healthy tissues.
VELOS™ creates a clonal neoantigen-reactive T cell product, or cNeT, by using the power of natural antigen presentation by dendritic cells to selectively expand T cells that are reactive against the identified clonal neoantigens. cNeT products target multiple clonal neoantigens in a patient and exploit cancer’s Achilles heel, allowing precision treatments that destroy tumors without harming healthy tissues.